Replidyne Sets IPO Pricing

Louisville, Colorado-based Replidyne has set the terms of its IPO, saying in a regulatory filing today that it plans to offer up to five million shares of stock for between $14.00 and $16.00 per share. The company is looking to raise up to $92M on the Nasdaq under the ticker symbol RDYN. The IPO is being underwritten by Merrill Lynch & Co., Morgan Stanley, Cowen and Company, and Pacific Growth Equities. Replidyne is a venture backed firm that is developing anti-infective products, including a oral, community antibiotic focused on treating infections. The firm filed for an NDA with the FDA in December.